Myriad Genetics Inc
NASDAQ:MYGN
MYGN's latest stock split occurred on Mar 26, 2009
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
Before the split, MYGN traded at 84.96 per share. Afterward, the share price was about 39.186.
The adjusted shares began trading on Mar 26, 2009. This was MYGN's 2nd stock split, following the previous one in Sep 12, 2000.
88EDA
SBET
Myriad Genetics Inc
Glance View
Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds. Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.
You don't have any saved screeners yet